Auspex Prices IPO

La Jolla-based biopharmaceuticals developer Auspex Pharmaceuticals has priced its IPO, saying it will offer up 7,000,000 shares of its common stock at $12.00 per share. The company will begin trading this morning as ASPX on the NASDAQ Global Market. Auspex is developing treatments for Huntington's and other orphan diseases. The company is venture backed by Deerfield Management Company, Thomas, McNerney and Partners, CMEA Capital, Panorama Capital, BioMed Ventures and Costa Verde Capital. The company's IPO was underwritten by STifel, BMO Capital Marketings, Robert W. Baird & Co., William Blair, and Ladenburg Thalmann & Co.